|
1
|
Karlsson TR, Al-Azzawe M, Aziz L, Hurman D
and Finizia C: Survival outcome depending on different treatment
strategies in advanced stages III and IV laryngeal cancers: An
audit of data from two European centres. Eur Arch Otorhinolaryngol.
271:547–554. 2014. View Article : Google Scholar
|
|
2
|
Haapaniemi A, Koivunen P, Saarilahti K,
Kinnunen I, Laranne J, Aaltonen LM, Närkiö M, Lindholm P, Grénman
R, Mäkitie A, et al The Finnish Head and Neck Oncology Working
Group: Laryngeal cancer in Finland: A 5-year follow-up study of 366
patients. Head Neck. 00:00. 2014.
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nichols AC, Whelan F, Basmaji J, Dhaliwal
S, Dowthwaite S, Chapeskie C, Read N, Palma DA, Fung K, Venkatesan
V, et al: Ki-67 expression predicts radiotherapy failure in early
glottic cancer. J Otolaryngol Head Neck Surg. 41:124–130.
2012.PubMed/NCBI
|
|
5
|
Nix P, Cawkwell L, Patmore H, Greenman J
and Stafford N: Bcl-2 expression predicts radiotherapy failure in
laryngeal cancer. Br J Cancer. 92:2185–2189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshida K, Sasaki R, Nishimura H, Okamoto
Y, Suzuki Y, Kawabe T, Saito M, Otsuki N, Hayashi Y, Soejima T, et
al: Nuclear factor-kappaB expression as a novel marker of
radioresistance in early-stage laryngeal cancer. Head Neck.
32:646–655. 2010.
|
|
7
|
Bussink J, van der Kogel AJ and Kaanders
JH: Activation of the PI3-K/AKT pathway and implications for
radioresistance mechanisms in head and neck cancer. Lancet Oncol.
9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jonathan RA, Wijffels KI, Peeters W, de
Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ and
Kaanders JH: The prognostic value of endogenous hypoxia-related
markers for head and neck squamous cell carcinomas treated with
ARCON. Radiother Oncol. 79:288–297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoogsteen IJ, Marres HA, Bussink J, van
der Kogel AJ and Kaanders JH: Tumor microenvironment in head and
neck squamous cell carcinomas: Predictive value and clinical
relevance of hypoxic markers. A review. Head Neck. 29:591–604.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bussink J, Kaanders JH and van der Kogel
AJ: Tumor hypoxia at the micro-regional level: Clinical relevance
and predictive value of exogenous and endogenous hypoxic cell
markers. Radiother Oncol. 67:3–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Airley R, Loncaster J, Davidson S, Bromley
M, Roberts S, Patterson A, Hunter R, Stratford I and West C:
Glucose transporter glut-1 expression correlates with tumor hypoxia
and predicts metastasis-free survival in advanced carcinoma of the
cervix. Clin Cancer Res. 7:928–934. 2001.PubMed/NCBI
|
|
12
|
Luo XM, Zhou SH and Fan J: Glucose
transporter-1 as a new therapeutic target in laryngeal carcinoma. J
Int Med Res. 38:1885–1892. 2010. View Article : Google Scholar
|
|
13
|
Rademakers SE, Lok J, van der Kogel AJ,
Bussink J and Kaanders JH: Metabolic markers in relation to
hypoxia; staining patterns and colocalization of pimonidazole,
HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer. 11:167–176.
2011. View Article : Google Scholar
|
|
14
|
Zhou SH, Fan J, Chen XM, Cheng KJ and Wang
SQ: Inhibition of cell proliferation and glucose uptake in human
laryngeal carcinoma cells by antisense oligonucleotides against
glucose transporter-1. Head Neck. 31:1624–1633. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yan SX, Luo XM, Zhou SH, Bao YY, Fan J, Lu
ZJ, Liao XB, Huang YP, Wu TT and Wang QY: Effect of antisense
oligodeoxynucleotides glucose transporter-1 on enhancement of
radiosensitivity of laryngeal carcinoma. Int J Med Sci.
10:1375–1386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Melstrom LG, Salabat MR, Ding XZ, Milam
BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the
GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt
pathway in human pancreatic cancer cells. Pancreas. 37:426–431.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suh HN and Han HJ: Fibronectin-induced
VEGF receptor and calcium channel transactivation stimulate GLUT-1
synthesis and trafficking through PPARγ and TC10 in mouse embryonic
stem cells. Stem Cell Res (Amst). 10:371–386. 2013. View Article : Google Scholar
|
|
18
|
Zhao K, Yang SY, Zhou SH, Dong MJ, Bao YY
and Yao HT: Fluorodeoxyglucose uptake in laryngeal carcinoma is
associated with the expression of glucose transporter-1 and
hypoxia-inducible-factor-1α and the phosphoinositide
3-kinase/protein kinase B pathway. Oncol Lett. 7:984–990.
2014.PubMed/NCBI
|
|
19
|
Gonnella R, Santarelli R, Farina A,
Granato M, D'Orazi G, Faggioni A and Cirone M: Kaposi sarcoma
associated herpesvirus (KSHV) induces AKT hyperphosphorylation,
bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1
monocytic cell line. J Exp Clin Cancer Res. 32:792013. View Article : Google Scholar :
|
|
20
|
Heavey S, O'Byrne KJ and Gately K:
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Cancer Treat Rev. 40:445–456. 2014. View Article : Google Scholar
|
|
21
|
Kaidar-Person O, Lai C, Kuten A and
Belkacemi Y; AROME: 'The Infinite Maze̓ of breast cancer, signaling
pathways and radioresistance. Breast. 22:411–418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ni J, Cozzi P, Hao J, Beretov J, Chang L,
Duan W, Shigdar S, Delprado W, Graham P, Bucci J, et al: Epithelial
cell adhesion molecule (EpCAM) is associated with prostate cancer
metastasis and chemo/radioresistance via the PI3K/Akt/mTOR
signaling pathway. Int J Biochem Cell Biol. 45:2736–2748. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhuang W, Qin Z and Liang Z: The role of
autophagy in sensitizing malignant glioma cells to radiation
therapy. Acta Biochim Biophys Sin (Shanghai). 41:341–351. 2009.
View Article : Google Scholar
|
|
24
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: Acquisition of
epithelial-mesenchymal transition and cancer stem cell phenotypes
is associated with activation of the PI3K/Akt/mTOR pathway in
prostate cancer radioresistance. Cell Death Dis. 4:e8752013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carón RW, Yacoub A, Zhu X, Mitchell C, Han
SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S and Dent P: H-RAS
V12-induced radioresistance in HCT116 colon carcinoma cells is
heregulin dependent. Mol Cancer Ther. 4:243–255. 2005.PubMed/NCBI
|
|
26
|
Kao GD, Jiang Z, Fernandes AM, Gupta AK
and Maity A: Inhibition of phosphatidylinositol-3-OH kinase/Akt
signaling impairs DNA repair in glioblastoma cells following
ionizing radiation. J Biol Chem. 282:21206–21212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bao YY, Zhou SH, Fan J and Wang QY:
Anticancer mechanism of apigenin and the implications of GLUT-1
expression in head and neck cancers. Future Oncol. 9:1353–1364.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shukla S, Bhaskaran N, Babcook MA, Fu P,
Maclennan GT and Gupta S: Apigenin inhibits prostate cancer
progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Carcinogenesis. 35:452–460. 2014. View Article : Google Scholar :
|
|
29
|
Lee WJ, Chen WK, Wang CJ, Lin WL and Tseng
TH: Apigenin inhibits HGF-promoted invasive growth and metastasis
involving blocking PI3K/Akt pathway and beta 4 integrin function in
MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol.
226:178–191. 2008. View Article : Google Scholar
|
|
30
|
Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J,
Xu X, Xu X, Qin J and Xie L: Apigenin promotes apoptosis, inhibits
invasion and induces cell cycle arrest of T24 human bladder cancer
cells. Cancer Cell Int. 13:542013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY
and Chen H: Apigenin sensitizes doxorubicin-resistant
hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via
inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 34:1806–1814.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu YY, Wu TT, Zhou SH, Bao YY, Wang QY,
Fan J and Huang YP: Apigenin suppresses GLUT-1 and p-AKT expression
to enhance the chemosensitivity to cisplatin of laryngeal carcinoma
Hep-2 cells: An in vitro study. Int J Clin Exp Pathol. 7:3938–3947.
2014.PubMed/NCBI
|
|
33
|
Shukla S and Gupta S: Apigenin-induced
cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and
loss of cyclin D1 associated retinoblastoma dephosphorylation in
human prostate cancer cells. Cell Cycle. 6:1102–1114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang XQ, Chen X, Xie XX, Zhou Q, Li K, Li
S, Shen LF and Su J: Co-expression of CD147 and GLUT-1 indicates
radiation resistance and poor prognosis in cervical squamous cell
carcinoma. Int J Clin Exp Pathol. 7:1651–1666. 2014.PubMed/NCBI
|
|
35
|
Kunkel M, Moergel M, Stockinger M, Jeong
JH, Fritz G, Lehr HA and Whiteside TL: Overexpression of GLUT-1 is
associated with resistance to radiotherapy and adverse prognosis in
squamous cell carcinoma of the oral cavity. Oral Oncol. 43:796–803.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Doki Y, Takachi K, Ishikawa O, Sasaki Y,
Miyashiro I, Ohigashi H, Yano M, Ishihara R, Tsukamoto Y, Nishiyama
K, et al: Reduced tumor vessel density and high expression of
glucose transporter 1 suggest tumor hypoxia of squamous cell
carcinoma of the esophagus surviving after radiotherapy. Surgery.
137:536–544. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jacobs SR, Herman CE, Maciver NJ, Wofford
JA, Wieman HL, Hammen JJ and Rathmell JC: Glucose uptake is
limiting in T cell activation and requires CD28-mediated
Akt-dependent ad independent pathways. J Immunol. 180:4476–4486.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wieman HL, Wofford JA and Rathmell JC:
Cytokine stimulation promotes glucose uptake via
phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and
trafficking. Mol Biol Cell. 18:1437–1446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schuurbiers OC, Kaanders JH, van der
Heijden HF, Dekhuijzen RP, Oyen WJ and Bussink J: The
PI3-K/AKT-pathway and radiation resistance mechanisms in non-small
cell lung cancer. J Thorac Oncol. 4:761–767. 2009. View Article : Google Scholar : PubMed/NCBI
|
